Effect of Jiuwei Zhuhuang Powder on Cough Resolution in Children with Upper Respiratory Tract Infections: A Multicenter Randomized Controlled Trial

• Published in: Chinese journal of integrative medicine Vol. 28; no. 5; pp. 387 - 393
• Main Authors: Luo, Hui, Song, Gui-Hua, Ma, Xiao-jian, Sun, Meng-meng, Zhang, Man, Xie, Jian-rong, Peng, Shao
• Format: Journal Article
• Language: English
• Published: Singapore Springer Nature Singapore 01.05.2022
• Subjects: Child; Cough - drug therapy; Drugs, Chinese Herbal; Humans; Medicine; Medicine & Public Health; Nonprescription Drugs; Original; Original Article; Powders; Respiratory Tract Infections - drug therapy; Jiuwei Zhuhuang Powder; Tibetan medicine; upper respiratory tract infection; child cough; randomized controlled trial
• ISSN: 1672-0415; 1993-0402
• DOI: 10.1007/s11655-021-3462-x

Objective To assess the effectiveness of Jiuwei Zhuhuang Powder (JWZH), a Tibetan patent medicine in treating upper respiratory tract infection (URTI) associated cough in children. Methods The study was a multicenter, randomized, open-label, controlled trial. A total of 142 children aged 2 to 14 years old, with URTI-associated cough within 48 h of onset, were randomly assigned to two groups at a 1:1 ratio by computer-generated randomization sequence. Children were treated with JWZH (1 to 1.5 g, twice to thrice daily) in the treatment group or conventional treatment (Pediatric Paracetamol, Artificial Cow-bezoar and Chlorphenamine Maleate Granules, 0.25 to 1 g, thrice daily) in the control group for 5 days. The primary endpoints were the time to cough resolution and 4-day cough resolution rate. The secondary endpoints were the daily improvement in symptom scores and cough resolution rate during the study period. Results A total of 138 children were included in the intention-to-treat analysis, with 71 cases in the treatment group and 67 cases in the control group. Compared with the conventional treatment, the children receiving JWZH had a shorter time to cough resolution [hazard ratio, 2.10; 95% confidence interval (CI), 1.29–3.40; P =0.003]. The median time to cough resolution for children receiving JWZH was shorter than that of the conventional treatment (2 days vs. 3 days; P <0.001). The 4-day cough resolution rate in the JWZH group was higher than that of the control group (94.4% vs. 74.6%; risk difference: 19.8%, 95% CI: 8.1%–31.5%; relative risk: 1.265, 95% CI: 1.088–1.470; P =0.001). There were no statistically significant differences in the improvement of other symptoms caused by URTI ( P >0.05). Adverse events was reported in 5.6% (4/71) and 4.5% (3/67) in participants of JWZH and PPACCM groups ( P >0.05), respectively, which were all mild and resolved without treatment. Conclusion JWZH seemed to be a safe and effective therapy for URTI-associated cough in children. (Trial registration No. ChiCTR2000039421)